Brief: FDA Grants Orphan Drug Designation To Ns-051/Ncnp-04 For Treatment Of Duchenne Muscular Dystrophy
19/09/2025 17:18
Sept 19 (Reuters) - Nippon Shinyaku Co Ltd 4516.T: FDA GRANTS ORPHAN DRUG DESIGNATION TO NS-051/NCNP-04 FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Source text: ID:nPn1F6q6xa Further company coverage: 4516.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nippon Shinyaku
See all newsTable: Nippon Shinyaku -Q1 group results (IFRS)
Brief: Elixirgen Therapeutics And Nippon Shinyaku Enter Into An Option Agreement For The Development And Commercialization Of Exg-7001 For Duchenne Muscular Dystrophy
Table: Nippon Shinyaku -2025/26 group results (IFRS)
Table: Nippon Shinyaku -2025/26 parent results
Table: Nippon Shinyaku -9-MTH group results (IFRS)